BUSINESS
Rantidine impurity scare: Many doctors say they still have faith in the age-old drug
In September this year, the US FDA had announced that preliminary tests found low levels of N-nitrosodimethylamine (NDMA) in ranitidine and nizatidine.
BUSINESS
Why India needs to take a serious look at sale and consumption of tobacco
Projected tobacco-associated mortality in India is estimated reach 1.5 million by 2020
BUSINESS
Five things to watch out for in pharma and healthcare in 2020
Pharma and healthcare sectors are to some extent insulated from the general economic slowdown but a recessionary economy makes people go slow on elective surgeries.
BUSINESS
Rusan Pharma sets sight on becoming an end-to-end player in opioid drugs
Rusan has set an ambitious target of clocking sales worth Rs 1,000 crore in the next five years.
BUSINESS
Why timely action is crucial for saving stroke patients
As per ICMR report 2016 - stroke is the fourth leading cause of death and the fifth leading cause of disability.
BUSINESS
Niti Aayog looks to ensure patient safety and foster innovation in proposed Medical Devices Bill
The proposed law brings all medical devices under one regulatory regime in a phased manner, and rigour and oversight will be dependent on risk-based classification of medical devices.
BUSINESS
Here's what transpired in the Indian pharma and healthcare industry in 2019
The industry, which had a bad first-half, witnessed a rebound in the second-half of the year on the back of significant growth in domestic formulation businesses and strong exports.
BUSINESS
How Pune-based Cilicant is trying to disrupt MNC-dominated pharma desiccant market
In pharmaceuticals, desiccants play an important role in keeping the drugs stable and extending their shelf life.
BUSINESS
Vildagliptin's patent expiry to make way for new SGLT2-based drugs for type-2 diabetes treatment
The market for SGLT2 inhibitors stood around Rs 996 crore, as moving annual total (MAT) on November 2019, growing little above 20 percent.
BUSINESS
HCG to divest fertility division, focuses on tightening costs,paring debt
Fertility division contributed about 6.6 percent of the HCG's consolidated revenue of Rs 978.7 crore in FY19.
BUSINESS
NPPA pulls up drug cos for selling anti-diabetes pills without seeking approval for pricing exemption
The Drug price control order (DPCO), 2013 provisions doesn't apply to drugs for up to five years developed through indigenous research and development, which means they are exempted from any price regulation.
BUSINESS
Pharma wrap: NPPA drug price hike and the need for robust price regulation of medicines
NPPA said it considered the view that unviability of these formulations should not lead to a situation where these drugs become unavailable in the market and that the public is forced to switch to costly alternatives
BUSINESS
NPPA hikes ceiling prices of 21 formulations by 50%
Most of these drugs are used as first line of treatment and are crucial to the public health program of the country. Many companies have applied for discontinuation of the product on account of unviability.
BUSINESS
Betting big on its upcoming facility in Gujarat, Ascent Meditech sets ambitious revenue target
Rajiv Mistry, Founder and Managing Director of Ascent Meditech, said the company purchased 12 acres of land in South Gujarat to set up the new facility.
BUSINESS
Novartis sees larger India role in its drug development value chain
Arno Tellmann, Head Global Drug Development India, said that the GDD in Hyderabad over the years has evolved from just being a back-office support function to playing a much bigger role in drug development work of Novartis.
BUSINESS
Biocon extends licensing pact for Itolizumab with Equillium for Australia, NZ
Equillium had secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017
BUSINESS
Pharma market grows 14.5% in November, respiratory drugs lead
While the anti-infectives grew at 17 percent in November, respiratory segment grew at 19.7 percent.
BUSINESS
Anti-diabetes drug Vildagliptin to become 80% cheaper
The patents for Vildagliptin in India held by Novartis were expired on December 9, opening the market for cheap rip-offs.
BUSINESS
Medical tourists help Indian hospitals beat slump in domestic market
According to EY, India has 38 Joint Commission International- accredited hospitals, the fourth highest after Brazil, Thailand and Turkey.
BUSINESS
Pharma wrap: Why we need to give teeth to regulation to curb unethical pharma marketing practices
The study's key findings point towards the trends in promotional strategies which have shifted from providing scientific information to doctors to merely focusing on business generation at all costs.
BUSINESS
Health activists oppose Sanofi's patent applications for TB medicine in India
The argument put forth by the activists is that Sanofi's patent claims are not a new invention but simply a combination of two existing drugs.
BUSINESS
E-pharmacies urge govt to finalise rules to regulate industry, end uncertainty
Most e-pharmacies are operating in the country without a drug licence as there are no rules framed for the sector.
BUSINESS
Mankind Pharma becomes first Indian company to launch women-health therapy Dydrogesterone
Dydrogesterone has a similar molecular structure to natural progesterone but it has enhanced bioavailability and fewer side-effects.
BUSINESS
Cadila Healthcare files NDA with DCGI for liver disease drug Saroglitazar Mg
If the latest NDA is approved, Saroglitazar Mg could become the first medicine indicated for the treatment of Non-alcoholic Steatohepatitis (NASH).
